Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Remibrutinib maintained robust clinical efficacy throughout
treatment period, with fast onset of action in CSU (1/3)
Dose-response with significant improvements
vs. placebo
Rapid and significant improvement in UAS7
over 12 weeks vs. placebo
Change from Baseline in UAS7 score
0
-5-
-10-
-15-
-20-
-25
max T-Statistics = 6.67, p<0.0001
-30
0
10
20
35
50
100
200
Total Daily Dose (mg)
q.d.
O b.i.d.
q.d.
b.i.d.
q.d.
--- b.i.d.
Change from baseline (LS mean + 90% CI)
0
-10-
-15-
-20
-25
0
1
5
6
7
8
9
10
11
12
Time (Weeks)
LOU064 10mg q.d.(N=44)
LOU064 25mg b.i.d.(N=43)
LOU064 35mg q.d.(N=44)
LOU064 100mg b.i.d.(N=45)
LOU064 100mg q.d.(N=47)
--- Placebo(N=42)
LOU064 10mg b.i.d.(N=44)
Primary endpoint met; dose-response vs. placebo UAS7
change from baseline at Week 4
No safety signals
UAS7 scores improved from baseline up to Week 12
for all doses compared with placebo
Improvement was rapid (UAS7) as early as Week 1,
and maintained up to Week 12
AE Adverse events CSU - chronic spontaneous urticaria UAS7-weekly Urticaria Activity Score
b.i.d. two times a day
16 Investor Relations | Q3 2021 Results
3
INNOVATION
NOVARTIS | Reimagining MedicineView entire presentation